At BASS Medical Group, we are dedicated to advancing medical research and providing cutting-edge treatments to our patients. We are currently enrolling participants for several groundbreaking studies aimed at improving outcomes for patients with various types of cancer.
The PRESERVE-003 Study is a Phase 3 clinical trial investigating the safety and efficacy of a next-generation anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression on anti-PD-1/PD-L1 antibody-based therapy.
Study Objective
To evaluate whether gotistobart can prolong the life of NSCLC patients compared to the chemotherapy agent docetaxel.
Study Details
Patients will be randomized to receive treatment with either gotistobart or docetaxel via intravenous infusion once every 21 days for up to 17 cycles over approximately one year.
Open to patients with metastatic NSCLC who have experienced disease progression on anti-PD-1/PD-L1 antibody-based therapy.
Sponsored by Freenome
FRNM-005 Study
The FRNM-005 Study is a prospective blood sample collection study aimed at developing a method for detecting colorectal cancer (CRC) and advanced adenomas.
Cohort B (Focus Cohort)
Participants
Aged 45-85
Treatment naive
Confirmed CRC or Advanced Adenoma
Cohort A
Participants at average risk
Aged 45-85
Blood draw pre-colonoscopy
Study Details
Blood draw volume: 50 mL (5 x 10mL tubes)
Sponsored by CairnSurgical
Breast Cancer Locator Study
The Breast Cancer Locator Study is investigating the effectiveness of the Breast Cancer Locator System in guiding partial mastectomy for breast cancer compared to traditional wire localization.
Eligibility Criteria
Women
Aged >18 years
Histologic diagnosis of invasive breast cancer or DCIS
Non-palpable, unifocal tumor; possible satellite lesions <= 2cm from primary are eligible
Tumor >= 1cm in diameter visible on prone breast MRI imaging and mammography
Study Objective
To determine whether the Breast Cancer Locator System can improve a surgeon’s ability to reduce positive margins compared to traditional wire localization.
If you are interested in participating in any of these studies or would like more information, please contact BASS Medical Group. Your participation could contribute to advancements in cancer treatment and benefit patients worldwide. Thank you for considering joining us in the fight against cancer.
Contact the Clinical Trials Department for more information:
Brenna Lindsey, MPH
575 Lennon Lane, Suite 153
Walnut Creek, CA 94598
Brenna.lindsey@bassmedicalgroup.com
Disclaimer: Participation in clinical trials is voluntary, and potential risks and benefits will be discussed with qualified medical personnel.
